EPIZYME INC's ticker is EPZM and the CUSIP is 29428V104. A total of 117 filers reported holding EPIZYME INC in Q3 2021. The put-call ratio across all filers is 1.61 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $19,000 | -62.0% | 12,840 | -70.5% | 0.00% | – |
| Q1 2022 | $50,000 | -42.5% | 43,486 | +25.6% | 0.00% | – |
| Q4 2021 | $87,000 | -49.1% | 34,618 | +3.8% | 0.00% | – |
| Q3 2021 | $171,000 | -50.6% | 33,348 | -19.9% | 0.00% | -100.0% |
| Q2 2021 | $346,000 | +4.8% | 41,616 | +9.7% | 0.00% | 0.0% |
| Q1 2021 | $330,000 | -14.3% | 37,919 | +7.0% | 0.00% | 0.0% |
| Q4 2020 | $385,000 | +18.1% | 35,437 | +29.8% | 0.00% | -50.0% |
| Q3 2020 | $326,000 | -28.2% | 27,291 | -3.5% | 0.00% | 0.0% |
| Q2 2020 | $454,000 | +62.7% | 28,271 | +57.1% | 0.00% | 0.0% |
| Q1 2020 | $279,000 | -64.2% | 17,999 | -43.2% | 0.00% | -50.0% |
| Q4 2019 | $779,000 | +125.8% | 31,663 | -5.4% | 0.00% | +100.0% |
| Q3 2019 | $345,000 | -16.3% | 33,487 | +2.0% | 0.00% | 0.0% |
| Q2 2019 | $412,000 | -0.5% | 32,817 | -1.7% | 0.00% | 0.0% |
| Q1 2019 | $414,000 | +102.9% | 33,385 | +0.8% | 0.00% | +100.0% |
| Q4 2018 | $204,000 | -44.6% | 33,110 | -4.7% | 0.00% | -50.0% |
| Q3 2018 | $368,000 | -24.7% | 34,743 | -3.7% | 0.00% | -33.3% |
| Q2 2018 | $489,000 | -28.1% | 36,094 | -5.7% | 0.00% | -25.0% |
| Q1 2018 | $680,000 | +21.4% | 38,295 | -14.1% | 0.00% | 0.0% |
| Q4 2017 | $560,000 | -17.8% | 44,597 | +24.7% | 0.00% | -33.3% |
| Q3 2017 | $681,000 | +34.3% | 35,767 | +6.5% | 0.01% | +20.0% |
| Q2 2017 | $507,000 | -16.9% | 33,599 | -5.6% | 0.01% | -16.7% |
| Q1 2017 | $610,000 | +12.5% | 35,595 | -20.5% | 0.01% | 0.0% |
| Q4 2016 | $542,000 | +36.2% | 44,788 | +10.6% | 0.01% | 0.0% |
| Q3 2016 | $398,000 | -18.3% | 40,489 | -14.8% | 0.01% | 0.0% |
| Q2 2016 | $487,000 | -14.9% | 47,522 | +0.8% | 0.01% | -25.0% |
| Q1 2016 | $572,000 | -5.5% | 47,158 | +24.9% | 0.01% | +14.3% |
| Q4 2015 | $605,000 | +37.2% | 37,764 | +10.1% | 0.01% | +16.7% |
| Q3 2015 | $441,000 | -49.8% | 34,298 | -6.3% | 0.01% | -50.0% |
| Q2 2015 | $878,000 | +56.0% | 36,588 | +22.0% | 0.01% | +71.4% |
| Q1 2015 | $563,000 | +17.5% | 30,002 | +18.2% | 0.01% | +16.7% |
| Q4 2014 | $479,000 | -21.1% | 25,378 | +13.3% | 0.01% | -25.0% |
| Q3 2014 | $607,000 | -26.1% | 22,391 | -15.1% | 0.01% | -27.3% |
| Q2 2014 | $821,000 | +13.1% | 26,370 | -17.3% | 0.01% | +22.2% |
| Q1 2014 | $726,000 | +170.9% | 31,881 | +147.2% | 0.01% | +125.0% |
| Q4 2013 | $268,000 | – | 12,895 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 31,833,334 | $47,750,000 | 19.42% |
| MPM BioImpact LLC | 3,425,202 | $3,939,000 | 1.06% |
| Palo Alto Investors LP | 6,774,541 | $7,791,000 | 0.60% |
| Foresite Capital Management I, LLC | 143,759 | $165,000 | 0.29% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 6,603,870 | $7,594,000 | 0.23% |
| Rock Springs Capital Management LP | 7,267,696 | $8,358,000 | 0.21% |
| BP PLC | 24,687 | $28,000 | 0.16% |
| NewGen Asset Management Ltd | 250,000 | $288,000 | 0.13% |
| GSA CAPITAL PARTNERS LLP | 467,836 | $538,000 | 0.07% |
| Frazier Life Sciences Management, L.P. | 739,369 | $850,000 | 0.07% |